3rd Quarter - Report
ARNOLD & PORTER KAYE SCHOLER LLP for ADAPTIVE BIOTECHNOLOGIES
Client
Income
$80,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Support for immune-driven biotechnologies platforms. VALID Act of 2020 (H.R. 6102/S. 3404), VITAL Act of 2020 (S. 3512), Eliminating Kickbacks in Recovery Act of 2018, 21st Century Cures Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KRISTINE BLACKWOOD | — |
| CASEY BROUHARD | — |
| CJ MAHLER | — |
| EUGENIA PIERSON | — |
Health Issues HCR
Support for immune-driven biotechnologies platforms. VALID Act of 2020 (H.R. 6102/S. 3404), VITAL Act of 2020 (S. 3512), Eliminating Kickbacks in Recovery Act of 2018, 21st Century Cures Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KRISTINE BLACKWOOD | — |
| CASEY BROUHARD | — |
| CJ MAHLER | — |
| EUGENIA PIERSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.